--- title: "New Advances in Hematology and Autoimmune Care: New Therapies, New Drug Access and More Affordable, Patient-Friendly Care" url: "https://www.yyhmedical.com/en/news/hematology-autoimmune-breakthrough-new-drugs-affordable-care" type: Article inLanguage: en-US category: Medical Advances datePublished: 2026-04-28 --- # New Advances in Hematology and Autoimmune Care: New Therapies, New Drug Access and More Affordable, Patient-Friendly Care > A roundup of recent developments patients may want to know about, including CAR-T therapy for lupus, consolidation options for central nervous system lymphoma, low-dose CD7 CAR-T, a newly available pediatric leukemia CAR-T therapy, and the National Pediatric Cancer Surveillance Annual Report (2024). Summary: Recent developments in hematology and oncology include encouraging results with autologous CD19 CAR-T therapy for systemic lupus erythematosus, with the potential for sustained drug-free remission; evidence supporting autologous stem cell transplantation (ASCT) as a preferred consolidation option for chemosensitive relapsed/refractory central nervous system lymphoma; a reported 92.5% overall response rate with low-dose CD7 CAR-T therapy in T-cell lymphoma; the first use in Beijing of the pediatric CAR-T product puzolcabtagene autoleucel, now included in Beijing Puhui Health Insurance special-drug coverage; and new national data showing a 76.42% overall 5-year survival rate for childhood cancer in China. Together, these updates offer patients and families a practical overview of recent progress in treatment and care. For people living with blood disorders or cancer, advances in treatment and the arrival of new therapies can directly affect treatment options, quality of life, and access to care. Recent research findings, authoritative data releases and healthcare policy updates offer useful information for patients, families and healthcare professionals. Here is a concise roundup of several key developments, with a focus on what they may mean for patients. **Autologous CD19 CAR-T for Systemic Lupus Erythematosus: A Step Toward Drug-Free Remission** A team led by Dr. Jing PAN, who holds appointments at both the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, and Beijing GoBroad Hospital, together with Prof. Xiaoming Feng's team at the School of Basic Medical Sciences, Hangzhou Normal University, recently published an important study in Molecular Therapy on autologous CD19 CAR-T cell therapy for systemic lupus erythematosus (SLE). Many people with SLE require long-term immunosuppressive therapy, which can bring cumulative side effects and still may not fully prevent disease flares. The study enrolled 18 patients who had not responded adequately to multiple immunosuppressive treatments, including 15 children, and treated them with autologous CD19 CAR-T cells. The safety profile was generally favorable, with mostly mild adverse effects. At 6 months, 14 patients had achieved remission, and most were able to stop immunosuppressive medication, suggesting a potential path toward sustained drug-free remission. (Source: BioArtMED) ![28241cd8-7c69-4c4e-98e6-5768aa6be4d2.png](https://gaobo-byh-h5.oss-accelerate.aliyuncs.com/images/20260914/6d61e7488fa388ba6945a0b84fa56dc0_20260914020610.png "6d61e7488fa388ba6945a0b84fa56dc0_20260914020610.png")  **Relapsed/Refractory CNS Lymphoma: ASCT Remains a Preferred Consolidation Option for Chemosensitive Patients** Relapsed or refractory central nervous system lymphoma (R/R CNSL) can be difficult to treat, and choosing the right consolidation strategy after a patient responds to salvage therapy is especially important. A recent study from Dr. Kai HU's team at Beijing GoBroad Hospital, published in Cancer Immunology, Immunotherapy, compared consolidation approaches in this setting. The study included 60 patients who had regained complete remission and compared outcomes after autologous stem cell transplantation (ASCT) versus CAR-T therapy as consolidation. Three-year progression-free survival was 80% in the ASCT group versus 64.8% in the CAR-T group, and the cumulative incidence of relapse or progression was lower with ASCT (20% vs. 30.2%). The benefit was particularly notable in patients with primary CNS lymphoma. In practical terms, ASCT remains a preferred consolidation option for eligible, chemosensitive patients, while CAR-T may be considered for patients who are not candidates for ASCT. (Source: Xueye Shixun) ![4139ffa0-c848-4cc4-ae5c-2bb8a2e195ad.png](https://gaobo-byh-h5.oss-accelerate.aliyuncs.com/images/20260914/ebc8b2d335a699b27241c868ce77acfe_20260914020629.png "ebc8b2d335a699b27241c868ce77acfe_20260914020629.png")  **Low-Dose CD7 CAR-T for Relapsed/Refractory T-Cell Lymphoma: High Response Rate with Manageable Toxicity** Relapsed or refractory T-cell lymphoma remains challenging, particularly for patients with chemotherapy resistance, high tumor burden or rapidly progressive disease. Dr. Fan YANG from the team led by Dr. Kai HU at Beijing GoBroad Hospital recently published a study in Blood Cancer Journal exploring a low-dose CD7 CAR-T strategy. The study enrolled 40 patients with difficult-to-treat disease and used a low dose of 1 x 10^5 (+/-30%) CAR-T cells/kg. The overall response rate reached 92.5%, while the risk of severe infection was substantially reduced. A key goal of this strategy is to rapidly lower tumor burden and create a treatment window for patients to proceed to allogeneic hematopoietic stem cell transplantation (allo-HSCT). Follow-up data showed improved 2-year survival among patients who bridged to transplant, offering another potential pathway for patients with otherwise very limited treatment options. (Source: Xueye Shixun) ![b6c79bd5-62df-4ae4-be5a-5596ece5db8f.png](https://gaobo-byh-h5.oss-accelerate.aliyuncs.com/images/20260914/6e1164618cb5258dbcc57ec2744853da_20260914020645.png "6e1164618cb5258dbcc57ec2744853da_20260914020645.png")  **Pediatric Leukemia: First Beijing Use of puzolcabtagene autoleucel** Families of children with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) recently received an important new treatment update: puzolcabtagene autoleucel injection (brand name: Pulidekai®), China's first domestically developed Class 1 biologic CAR-T therapy approved for children and adolescents with this indication, has now been administered to a patient at Beijing GoBroad Hospital. The treatment was delivered by the team led by Dr. Jing PAN, Director of the Department of Hemato-Oncology & Immunotherapy at Beijing GoBroad Hospital. The therapy has also been included in the special-drug coverage of Beijing Puhui Health Insurance, a city-customized supplementary commercial health insurance program. This may help reduce the financial burden of treatment and improve access for more eligible children and families. (Source: Beijing GoBroad Hospital) ![628244fc-f2c6-4571-8dc7-6ca73d44aa0d.png](https://gaobo-byh-h5.oss-accelerate.aliyuncs.com/images/20260914/7ba343934d5612aebfd3d57d0c225f5d_20260914020712.png "7ba343934d5612aebfd3d57d0c225f5d_20260914020712.png")  **National Pediatric Cancer Surveillance Annual Report (2024) Released** On April 25, 2026, the National Center for Pediatric Cancer Surveillance officially released the National Pediatric Cancer Surveillance Annual Report (2024) at the China National Convention Center in Beijing. As one of China's most comprehensive and authoritative annual reports on childhood cancer surveillance, it provides important information relevant to diagnosis and treatment, rehabilitation, long-term survival and family support. ![4c46781d-b897-47f4-8dae-88e936fd1c15.png](https://gaobo-byh-h5.oss-accelerate.aliyuncs.com/images/20260914/ede5f29690952d1b587c3e56f0d40491_20260914020728.png "ede5f29690952d1b587c3e56f0d40491_20260914020728.png")  According to the report, the overall 5-year survival rate for childhood cancer in China has reached 76.42%. The surveillance network now covers 1,750 medical institutions across 29 provincial-level regions and includes data from more than 410,000 pediatric cancer patients. The report describes survival differences by cancer type, age and sex, and identifies the first year after diagnosis as a key window for improving long-term outcomes. It also places greater emphasis on long-term follow-up for childhood cancer survivors, including physical and mental health, late complications, psychological support and the financial burden on families. These data provide an important evidence base for childhood cancer care, rehabilitation services, charitable assistance and family support across China. (Sources: National Center for Pediatric Cancer Surveillance, Xinhua News Agency and CCTV News) --- Original (HTML):https://www.yyhmedical.com/en/news/hematology-autoimmune-breakthrough-new-drugs-affordable-care This is a clean Markdown mirror for large language models; the original page is authoritative.